Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Novartis Meningococcal B Recombinant Vaccine in At-risk Adults
NCT01478347Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2013
- Primary completion
- Mar 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal disease, meningococcal meningitis, sponsored by Novartis. Started May 2013; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal diseasemeningococcal meningitis
Beyond the preview
Go deeper on NCT01478347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01478347.